Figure 2 Kaplan-Meier

Figure 2. Kaplan–Meier estimate of the cumulative probability of a first hospitalisation for HF during the first 30 days after randomisation. The analysis at 30 days was prespecified and also represented the earliest time point at which the difference between the sacubitril/valsartan and enalapril groups was statistically significant.20 *ARR based on the number of first HF hospitalisation events up to day 30. Reproduced with permission from Packer M, McMurray JJ, Desai AS, et al. Circulation 2015;131:54–61. c 2014 American Heart Association, Inc

Figure 2. Kaplan–Meier estimate of the cumulative probability of a first hospitalisation for HF during the first 30 days after randomisation. The analysis at 30 days was prespecified and also represented the earliest time point at which the difference between the sacubitril/valsartan and enalapril groups was statistically significant.20 *ARR based on the number of first HF hospitalisation events up to day 30. Reproduced with permission from Packer M, McMurray JJ, Desai AS, et al. Circulation 2015;131:54–61. c 2014 American Heart Association, Inc